Lower strength patch added to Durogesic DTrans range

Janssen-Cilag has added a new lower strength patch to its Durogesic DTrans range, releasing fentanyl 12 micrograms per hour.

The Durogesic DTrans range, which includes patches releasing fentanyl 25, 50, 75 or 100 micrograms per hour, is indicated for use in the management of chronic intractable pain, including that caused by cancer.

The recommended starting dose for opioid-naive patients is one 25 micrograms per hour patch. For opioid tolerant patients the starting dose should reflect their previous 24-hour opioid analgesic requirement (refer to the Summary of Product Characteristics for further information).

The dose should be titrated individually until pain is controlled. Availability of the 12 micrograms per hour patch allows physicians to perform finer titration steps between 25 micrograms per hour and 75 micrograms per hour. Additional or alternative analgesics should be considered if the Durogesic DTrans dose exceeds 300 micrograms per hour.

Patients should apply the patch to a clean, dry, non-hairy area of the torso or upper arm and wear it continuously for 72 hours. The patch should then be removed and a new patch applied to a different site. Patches should not be cut or divided.

Once titrated to an effective dose, patients should not be changed to other transdermal fentanyl patches without retitration and clinical assessment.

Safety and efficacy of Durogesic DTrans in children have not been established and its use in this age group is not recommended.

View Durogesic DTrans drug record

Further information: Janssen-Cilag Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases